About Eiger BioPharmaceuticals
Eiger BioPharmaceuticals is a company based in San Carlos (United States) founded in 2000. Eiger BioPharmaceuticals has raised $8.9 million across 7 funding rounds from investors including RA Capital, Perceptive Advisors and HBM Healthcare Investments. The company has 56 employees as of December 31, 2022. Eiger BioPharmaceuticals operates in a competitive market with competitors including Spark Therapeutics, Denali Therapeutics, AskBio, Poseida Therapeutics and Castle Biosciences, among others.
- Headquarter San Carlos, United States
- Employees 56 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
$15.77 M (USD)17as on Dec 31, 2023
-
Net Profit
-$74.96 M (USD)23as on Dec 31, 2023
-
EBITDA
-$71.79 M (USD)23as on Dec 31, 2023
-
Total Equity Funding
$8.9 M (USD)
in 7 rounds
-
Latest Funding Round
$3 M (USD), Post-IPO
Apr 28, 2019
-
Investors
RA Capital
& 6 more
-
Employee Count
56
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Eiger BioPharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of Eiger BioPharmaceuticals
Eiger BioPharmaceuticals has successfully raised a total of $8.9M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $3 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Eiger BioPharmaceuticals
Eiger BioPharmaceuticals has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include RA Capital, Perceptive Advisors and HBM Healthcare Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life sciences focused VC firm funding companies in the US and Europe
|
Locked | Locked | Locked | |
|
Venture capital and private equity firm
|
Locked | Locked | Locked | |
|
Early-stage investing in IT and healthcare ventures.
|
Locked | Locked | Locked |
Investor details for Eiger BioPharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eiger BioPharmaceuticals
Investment portfolio details for Eiger BioPharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Eiger BioPharmaceuticals
Detailed financials for Eiger BioPharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eiger Biopharmaceuticals Comparisons
Peer comparison for Eiger BioPharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Eiger BioPharmaceuticals
Eiger BioPharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spark Therapeutics, Denali Therapeutics, AskBio, Poseida Therapeutics and Castle Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
Detailed competitors of Eiger BioPharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eiger Biopharmaceuticals
Complete news archive for Eiger BioPharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eiger BioPharmaceuticals
Eiger BioPharmaceuticals was founded in 2000 and raised its 1st funding round 10 years after it was founded.
Eiger BioPharmaceuticals is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.
Eiger BioPharmaceuticals is a funded company, having raised a total of $8.9M across 7 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Eiger BioPharmaceuticals is 56.
Annual revenue of Eiger BioPharmaceuticals is $15.77M as on Dec 31, 2023.
Developer of antiviral agents against targets in the treatment of hepatitis. It offers a lead product candidate, avexitide a first-in-class GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism.
Eiger BioPharmaceuticals's top competitors include Spark Therapeutics, Juno Therapeutics and AskBio.
Eiger BioPharmaceuticals has 7 investors. Key investors include RA Capital, Perceptive Advisors, HBM Healthcare Investments, Vivo Capital, and InterWest.